Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEMO trial
2023-509534-18-01Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Apr 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of heparin in multiple myeloma (MM) and lymphoma (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Primary: Stem cell yield after first collection day. Planned start Apr 2024; status: authorised.
02
Drugs
heparin
03
Conditions
multiple myeloma (MM)lymphoma
Beyond the preview
Go deeper on 2023-509534-18-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509534-18-01.